a study of imc-a12 in participants with tumors who no longer respond to treatment or for whom no treatment is available

Conditions: Advanced Solid Tumors

Summary: the purpose of this study is to determine if imc-a12 is safe for participants, and also to determine the best dose of imc-a12 to give to participants.

the purpose of this study is to establish the safety profile and maximum tolerated dose (mtd) of the anti-igf-ir monoclonal antibody imc-a12 administered weekly in participants with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available

Eligibility criteria:
inclusion criteria: * histopathologically-documented, measurable, advanced primary or recurrent solid tumors that no longer respond to standard therapy or for which no standard therapy is available. * eastern cooperative oncology group (ecog) performance status score of ≤2 at study entry * able to provide written informed consent * life expectancy of \>3 months * adequate hematologic functions, as defined by: absolute neutrophil count (anc) ≥1500/cubic millimeter (mm³), hemoglobin level ≥10 grams/deciliter (gm/dl), platelet count ≥100,000/mm³ * adequate hepatic function, as defined by: total bilirubin level ≤1.5 x the upper limit of normal (uln), aspartate transaminase (ast) and alanine transaminase (alt) levels ≤2.5 x the uln or ≤5 x the uln if known liver metastases * adequate renal function, as defined by a serum creatinine level ≤1.5 x the uln * ejection fraction within the normal institutional limits * use of effective contraception per institutional standard, if procreative potential exists * at least 28 days must have elapsed from major surgery, prior chemotherapy, prior treatment with an investigational agent or device, prior radiation therapy (palliative radiation therapy is allowed), an open biopsy, or a significant traumatic injury to allow for adequate recovery. ongoing side effects due to these agents must be ≤grade 2 prior to entering the study. * at least 6 weeks must have elapsed from nitrosoureas, mitomycin c, or monoclonal antibody \[not targeting the insulin-like growth factor receptor (igfr)\] therapy to allow for adequate recovery. ongoing side effects due to these agents must be ≤grade 2 prior to entering the study. * accessible for treatment and follow-up. participants enrolled in this trial must be treated at the participating center. exclusion criteria: * any concurrent malignancy other than non-melanomatous skin cancer or carcinoma in situ of the cervix. participants with a previous malignancy but without evidence of disease for ≥3 years will be allowed to enter the trial. * uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics, symptomatic congestive heart failure, unstable angina pectoris, angioplasty, stenting or myocardial infarction within 6 months, uncontrolled hypertension, clinically significant cardiac arrhythmia, psychiatric illness/social situations that would compromise participant safety or limit compliance with study requirements, participants with symptomatic brain metastases * serious or nonhealing active wound, ulcer or bone fracture * know human immunodeficiency virus (hiv)-positive * history of hemorrhagic or thrombotic disorder within 9 months * proteinuria ≥1+ by routine urinalysis (participants with a protein value of ≤500 milligrams (mg) confirmed by a 24-hour urine collection are eligible) * pregnant \[confirmed by serum beta human chorionic gonadotropin (βhcg)\] or breast feeding * history of prior treatment with other agents specifically targeting igfrs * known diabetes * inability or unwillingness to interrupt steroidal or hormonal therapy for the duration of treatment with imc-a12 * positive anti-imc-a12 antibody response * history of allergic reactions to monoclonal antibodies or other therapeutic proteins * employees of the investigator or study center with direct involvement in this study or other studies under the direction of the investigator or study center, as well as family members of the employees.

Keywords: tumors antibodies, monoclonal